# Gene Therapy for Wet AMD

> **NCT05611424** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Frontera Therapeutics** · enrollment: 18 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **GENETIC:** FT-003

## Key facts

- **NCT ID:** NCT05611424
- **Lead sponsor:** Frontera Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2024-11-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-04-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05611424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05611424, "Gene Therapy for Wet AMD". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05611424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*